Table 6.

The recovery of AKI in 214 patients infected by SARS-CoV and 66 patients infected by SARS-CoV-2 from the date of initial AKI event

Creatinine LevelSARS-CoV
At d 0 (n=214)At d 7 (n=139)At d 30 (n=85)At d 90 (n=70)P valuea,bP valuec
Median (IQR)140 (114–196)99 (68–191)75 (57–108)75 (63–103)<0.001a
No AKI/AKD/CKD, n (%)0 (0)94 (67.6)67 (77.9)58 (82.9)<0.001b0.17c
AKI stage 1, n (%)177 (82.7)19 (13.7)AKD 19 (22.1)CKD 12 (17.1)
AKI stage 2, n (%)17 (7.9)3 (2.2)
AKI stage 3, n (%)20 (9.3)23 (16.5)
Creatinine LevelSARS-CoV-2
At d 0 (n=66)At d 7 (n=65)At d 30 (n=63)At d 90 (n=63)P valuea,bP valuec
Median (IQR)108 (91–129)83 (69–103)75 (67–97)75 (66–94)<0.001a
No AKI/AKD/CKD, n (%)0 (0)55 (84.6)55 (87.3)58 (92.1)<0.001b0.20c
AKI stage 1, n (%)63 (95.5)3 (4.6)AKD 8 (12.7)CKD 5 (7.9)
AKI stage 2, n (%)3 (4.5)1 (1.5)
AKI stage 3, n (%)0 (0)6 (9.2)
P value0.009d0.005c
  • a Friedman test was used to compare creatinine level at d 0, 7, 30, and 90.

  • b Bhapkar test was used compare creatinine level and AKI status at d 0 and 7.

  • c Generalized estimating equations was used to compare presence of any AKI/AKD at d 7, 30, and 90.

  • d Categories of AKI/AKD between SARS-CoV and SARS-CoV-2 were compared by chi-squared test or Fisher’s exact test, as appropriate.